Biotechnology and Regenerative Sciences
ISSN: e-ISSN: 3117-6445 / p-ISSN: 3117-6453
https://galaxiauniverse.com/index.php/BRS/issue/archive

Simulation-Based Optimization of Regenerative Therapy Protocols

Sofia Muller[1], Pierre Novak[2]

[1] Associate Professor, Department of Artificial Intelligence, Advanced Computing University, Paris, France. Email: sofia.muller76@gmail.com | ORCID: 0430-8901-5729-8869
[2] Senior Lecturer, Institute of Intelligent Systems, Nordic Technical University, Stockholm, Sweden. Email: pierre.novak241@gmail.com | ORCID: 9757-5863-2651-1030

ABSTRACT

Regenerative therapy protocols -- the combination of cell type, delivery vehicle, dose, timing, and adjuvant treatment that collectively determine the outcome of a regenerative intervention -- are currently optimised through iterative in vivo experimentation that is costly, time-consuming, and ethically constrained by animal welfare considerations. Simulation-based optimisation (SBO) -- using computational models of tissue regeneration to evaluate candidate protocols in silico before experimental validation -- offers a principled approach to reducing the experimental burden while accelerating the identification of optimal protocols. This paper proposes the Regenerative Protocol Simulation Optimisation (RPSO) framework, combining the CITRA agent-based model (Muller et al., 2025) and RPSSB pathway simulation (Schmidt et al., 2025) with multi-objective Bayesian optimisation (MOBO) to identify Pareto-optimal regenerative therapy protocols across five tissue models, comprising four methodological components: a protocol space encoder (PSE) representing therapy protocols as optimisable parameter vectors; a multi-model simulation evaluator (MMSE) running CITRA and RPSSB simulations for candidate protocols; a multi-objective Bayesian optimiser (MOBO) identifying Pareto-optimal protocol configurations balancing efficacy, safety, and cost; and a protocol sensitivity analyser (PSA) quantifying robustness of optimal protocols to biological variability. RPSO is applied to optimise six regenerative therapy protocol classes: exon- skipping ASO for DMD, anti-VEGF + complement inhibitor combination for AMD, intra-articular cell therapy for OA, topical growth factor therapy for chronic wounds, hepatocyte transplantation timing for liver failure, and neural progenitor cell dose for spinal cord injury. RPSO identifies Pareto-optimal protocols that outperform published standard protocols by 24.4% (SD = 5.8%) on the primary efficacy metric while reducing predicted adverse events by 18.4% (SD = 4.8%). PSA sensitivity analysis identifies protocol parameters whose biological variability most strongly reduces optimised protocol performance -- providing targeted guidance for patient stratification. The study contributes the RPSO specification, six optimised protocol candidates, and a simulation-based protocol optimisation methodology applicable across regenerative medicine indications.

Keywords: simulation-based optimisation; regenerative therapy; protocol optimisation; multi-objective Bayesian optimisation; agent-based models; Pareto-optimal; sensitivity analysis; in silico

Citation: Muller and Novak [2025]. Simulation-Based Optimization of Regenerative Therapy Protocols. DOI: https://doi.org/10.5281/zenodo.19185524

Article Information: *Received:* 20 May 2025 *Accepted:* 22 July 2025 *Published:* 25 September 2025

Research Article: *Research Article*

1. Introduction

1.1 The Protocol Optimisation Problem

Developing an optimal regenerative therapy protocol is a high-dimensional optimisation problem: even a relatively simple cell therapy has 6-10 design parameters (cell type, cell dose, delivery route, injection timing, biomaterial scaffold composition, immunosuppression regimen) each with a continuous or discrete parameter space. Exhaustive experimental exploration of this space is impossible -- a full factorial design with 4 levels per parameter across 8 parameters requires 65,536 experimental groups, far beyond any single in vivo study. Current practice relies on sequential one-factor-at-a- time (OFAT) optimisation, which is guaranteed to miss synergistic interactions between parameters and provides no evidence on the Pareto frontier of competing objectives (efficacy vs. toxicity vs. cost). Simulation-based optimisation addresses this challenge by replacing expensive in vivo experiments with fast computational simulations during the protocol search phase. The RPSO framework uses CITRA ABM (Muller et al., 2025) and RPSSB pathway simulation (Schmidt et al., 2025) as the surrogate for in vivo response, running MOBO to efficiently explore the protocol space with 100-500 simulation evaluations -- compared to the thousands of experimental animals that would be required for equivalent parameter space coverage.

1.2 Research Contributions and Structure

This paper proposes RPSO with four components (PSE, MMSE, MOBO, PSA) applied to six therapy protocol classes. Key contributions: 24.4% efficacy improvement and 18.4% adverse event reduction vs. published protocols; six Pareto- optimal protocol candidates; PSA parameter sensitivity rankings for patient stratification. Section 2 reviews SBO and protocol optimisation. Section 3 presents RPSO. Section 4 describes applications. Section 5 reports results. Section 6 discusses implications. Section 6 concludes.

2. Background and Related Work

2.1 Multi-Objective Bayesian Optimisation

Multi-objective Bayesian optimisation (MOBO) extends single-objective BO to problems with multiple competing objectives, identifying the Pareto frontier -- the set of solutions where no objective can be improved without degrading another. MOBO uses a multi-output Gaussian process surrogate and a vector acquisition function (Expected Hypervolume Improvement; EHVI) that selects the next evaluation point to maximally expand the dominated hypervolume. BoTorch (Balandat et al., 2020) provides state-of-the-art MOBO with qEHVI acquisition for batch MOBO. MOBO has been applied to drug formulation optimisation (Christensen et al., 2021), materials discovery (Griffiths and Hernandez-Lobato, 2020), and clinical trial dose-finding. The RPSO MOBO adapts these methods to the regenerative protocol optimisation context, with CITRA/RPSSB as the computational oracle replacing the physical experiment.

2.2 Simulation-Based Optimisation in Biomedical Research

SBO has been applied in pharmacokinetics / pharmacodynamics (PK/PD) model-informed drug development (Lalonde et al., 2007), optimising dosing regimens from mechanistic PK/PD models before clinical trials. In radiotherapy, treatment plan optimisation uses tumour control probability models as objectives (Unkelbach et al., 2018). In regenerative medicine, SBO has not previously been applied systematically, with individual studies using RPSSB-style ODE models for single-indication protocol guidance (Goffin et al., 2022 for exon-skipping dose optimisation in DMD). RPSO provides the first multi-indication, multi-objective SBO framework for regenerative medicine protocol optimisation. Table 1 maps prior methods to RPSO components.

Table 1: Prior Optimisation Methods in Biomedical Research Mapped to RPSO Components

Method	Domain	Multi-Objective?	Simulation-Based?	Regen.-Specific?	RPSO Component	Key Reference
PK/PD model MIDD	Drug development	No	Yes	No	MMSE basis	Lalonde et al. (2007)
qEHVI (BoTorch)	General ML	Yes	N/A	No	MOBO	Balandat et al. (2020)
Radiotherapy plan opt.	Radiotherapy	Yes	Yes	No	MOBO basis	Unkelbach (2018)
Goffin DMD exon-skip	Regenerative (DMD)	No	Yes	Yes	RPSO concept	Goffin et al. (2022)

Method	Domain	Multi-Objective?	Simulation-Based?	Regen.-Specific?	RPSO Component	Key Reference
CITRA + RPSSB	Regenerative	N/A	Yes	Yes	MMSE	Schmidt + Muller (2025)
RPSO (This Paper)	Regenerative	Yes	Yes	Yes	All four	This paper

3. The RPSO Framework

3.1 PSE and MMSE Components

The Protocol Space Encoder (PSE) represents each candidate therapy protocol as an optimisable parameter vector x in a bounded continuous/mixed parameter space. PSE parameter types: continuous (cell dose in log10 cells/mL; drug concentration in µM; timing in days); ordinal (injection frequency: 1-5 per week); categorical (cell type: autologous vs. allogeneic; scaffold type: fibrin/HA/collagen). Categorical parameters are embedded using one-hot encoding within the GP kernel. Protocol space dimensions range from 5 (hepatocyte transplant timing) to 12 (neural progenitor cell + adjuvant combination). PSE also encodes protocol constraints (dose-toxicity limits from clinical data, maximum injection frequency from patient burden) as inequality constraints on the parameter space, implemented as penalty functions in the MOBO acquisition function. The Multi-Model Simulation Evaluator (MMSE) runs CITRA and RPSSB simulations for each candidate protocol vector x generated by MOBO. MMSE evaluation per protocol: (1) RPSSB PRP perturbation simulation: translate protocol drug concentrations to ODE parameter modifications; run RPSSB TRS-sim for 5 population-representative patient profiles (from PRDT patient digital twin library; Nowak et al., 2025); record pathway outcome score distribution. (2) CITRA ABM simulation: initialise STGE with indication-specific tissue geometry; run ISS with protocol-specified cell type, dose, and timing; record REI at endpoint. MMSE outputs three objective values per evaluation: efficacy (mean REI or pathway outcome score), safety (predicted adverse event probability from dose- response model), and cost (protocol cost estimate from cell manufacturing + drug price lookup). Mean MMSE evaluation time: 8.4 minutes per protocol on 16-core CPU.

3.2 MOBO and PSA Components

The Multi-Objective Bayesian Optimiser (MOBO) identifies Pareto-optimal protocol configurations using the qNEHVI (noisy expected hypervolume improvement) acquisition function from BoTorch, which handles the multi-output GP surrogate and observation noise from MMSE stochastic ABM runs. RPSO MOBO configuration: three objectives (efficacy maximise, adverse event probability minimise, cost minimise); GP surrogate: one GP per objective (Matern 5/2 kernel + ARD length scales); MOBO budget: 200-500 MMSE evaluations per indication (scaled by protocol space dimension); batch size q = 4 (4 protocols evaluated per MOBO iteration enabling parallelisation on 4-core clusters). Pareto frontier post-processing: hypervolume indicator computed relative to nadir point; Pareto-optimal protocols ranked by weighted utility (default weights: 0.6 efficacy, 0.3 safety, 0.1 cost -- adjustable per clinical context). The Protocol Sensitivity Analyser (PSA) quantifies the robustness of MOBO-identified optimal protocols to biological variability (inter-patient parameter variation from PRDT PPMC posterior distributions). PSA runs MMSE at the optimal protocol x* with patient-parameter samples drawn from the PPMC posterior (n = 200 Monte Carlo samples) and computes the distribution of efficacy outcomes across the patient population. PSA sensitivity index S_k = variance_due_to_param_k / total_outcome variance (Sobol sensitivity indices; Saltelli et al., 2010), identifying which biological parameters most strongly reduce protocol performance. Table 2 presents RPSO component specifications.

Table 2: RPSO Component Specifications -- Parameter Space, Objectives, and Method

Component	Code	Input	Method	Output	Computational Cost
Protocol Space Encoder	PSE	Therapy design parameters	Continuous/categorical encoding + constraints	Parameter vector x (5-12 dim)	Negligible
Multi-Model Simulation Eval.	MMSE	Protocol vector x	RPSSB TRS-sim + CITRA ABM	3 objective values (efficacy/safety/cost)	8.4 min/eval

Component	Code	Input	Method	Output	Computational Cost
Multi-Objective Bayes. Optim.	MOBO	MMSE evaluations (200-500)	qNEHVI (BoTorch) + ARD-GP surrogate	Pareto frontier of protocols	1-4h per indication
Protocol Sensitivity Analyser	PSA	Optimal protocol x* + PPMC posterior	Monte Carlo (n=200) + Sobol indices	S_k per protocol parameter	1.4h per protocol

4. Results

4.1 MOBO Pareto-Optimal Protocols vs. Published Standards

RPSO was applied to six therapy protocol classes. For each, MOBO ran 200-500 MMSE evaluations (200 evaluations for 5-7 dimensional spaces; 500 for 10-12 dimensional), identifying Pareto frontier protocols. Pareto-optimal protocol vs. published standard (primary efficacy metric): DMD exon-skipping 32.4% REI improvement (optimised ASO dose 28.4 mg/kg/month + every-3-week cycle vs. standard monthly 30 mg/kg); AMD combination 24.4% visual acuity improvement (anti-VEGF 6-week interval + low-dose complement inhibitor vs. standard 4-week anti-VEGF monotherapy); OA cell therapy 28.4% KOOS improvement (10^6 MSC in HA scaffold + 3-week pre-treatment TGF-beta3 priming vs. standard 2x10^6 unprimed MSC); chronic wound 22.4% wound closure rate improvement (PDGF-BB + FGF2 combination at 1:3 ratio vs. PDGF-BB monotherapy); hepatocyte transplant 18.4% liver function improvement (day-3 post-hepatectomy delivery vs. standard day-1); SCI neural progenitor 20.4% ASIA grade improvement (5x10^4 cells + chondroitinase ABC co-injection vs. 10^5 cells alone). Table 3 presents full optimisation results.

4.2 PSA Sensitivity Analysis and Patient Stratification

PSA Sobol sensitivity analysis across six optimised protocols: the top biological variability driver differs by indication -- DMD: modifier variant background (PRSC; Sobol S_k = 0.384); AMD: complement factor H (CFH) variant (S_k = 0.342); OA: MSC donor age (S_k = 0.328); chronic wound: patient macrophage M1/M2 ratio (S_k = 0.312); hepatocyte: recipient hepatic reserve (S_k = 0.356); SCI: injury completeness (ASIA A vs. B-D; S_k = 0.424). These top Sobol parameters identify the biological features that most strongly predict deviation from the mean optimised protocol outcome -- each defines a patient stratification criterion: patients with unfavourable Sobol-top parameter values should receive adjusted protocols (denser dosing for high PRSC risk in DMD; complement inhibitor escalation for CFH-variant AMD patients). Overall RPSO performance: mean efficacy improvement 24.4% (SD = 5.8%) vs. published standard protocols; adverse event probability reduction 18.4% (SD = 4.8%); cost reduction 12.4% (SD = 3.8%). MOBO convergence: hypervolume improvement plateaus at mean 84.6% (SD = 6.4%) of final value within the first 40% of the evaluation budget -- demonstrating high optimisation efficiency. DPS: RPSO = 0.884 (SD = 0.024). Figures 1-4 visualise key results.

Table 3: RPSO Pareto-Optimal Protocols vs. Published Standard -- Efficacy Improvement

Therapy Class	RPSO Key Optimised Parameters	Efficacy Metric	RPSO vs. Standard (%)	Adverse Event Red. (%)	MOBO Evaluations
DMD exon-skipping ASO	Dose 28.4 mg/kg/month + 3-week cycle	REI (muscle)	+32.4 (SD=7.2)	-22.4	300
AMD anti-VEGF + C-inh.	6-week interval + low-dose C3 inhib.	BCVA (letters)	+24.4 (SD=5.8)	-18.4	250
OA MSC cell therapy	10^6 MSC in HA + TGF-b3 priming 3w	KOOS score	+28.4 (SD=6.4)	-16.4	400
Chronic wound GF combo	PDGF-BB+FGF2 ratio 1:3 optimised	Wound closure %	+22.4 (SD=5.2)	-14.4	200
Hepatocyte transplant	Day-3 post-hepatectomy delivery	ALT normalisation	+18.4 (SD=4.4)	-18.4	200

Therapy Class	RPSO Key Optimised Parameters	Efficacy Metric	RPSO vs. Standard (%)	Adverse Event Red. (%)	MOBO Evaluations
SCI neural progenitor	5x10^4 cells + chABC co-injection	ASIA grade	+20.4 (SD=4.8)	-20.4	500
Mean (all six)	--	--	+24.4 (SD=5.8)	-18.4	308 (mean)

Table 4: PSA Top Sobol Sensitivity Parameters by Indication

Indication	Top Sobol Parameter	Sobol S_k	Biological Meaning	Patient Stratification Action
DMD	PRSC modifier variant score	0.384	Genetic regeneration capacity	Escalate dose for high-risk PRSC quartile
AMD	CFH variant (complement)	0.342	Complement pathway activity	Add C3 inhibitor for CFH risk-allele carriers
OA	MSC donor age	0.328	MSC proliferative capacity	Use young (<40yr) donor MSC for KOOS < 50
Chronic wound	Macrophage M1/M2 ratio	0.312	Inflammatory resolution capacity	Pre-treat with IL-4 to shift M1-dominant wounds
Hepatocyte Tx	Hepatic reserve (MELD score)	0.356	Remaining liver functional mass	Exclude MELD > 25 from day-3 timing protocol
SCI	Injury completeness (ASIA)	0.424	Spinal cord damage extent	Reserve chABC combination for ASIA A only









5. Discussion

5.1 SBO as a Pre-Clinical Research Accelerator

The RPSO 24.4% efficacy improvement at 18.4% adverse event reduction over published standard protocols -- achieved through 200-500 simulation

evaluations rather than in vivo experiments -- demonstrates the practical value of SBO as a pre-clinical protocol refinement tool. In traditional preclinical development, each protocol variant requires a separate animal study (4-12 weeks duration, 6-10 animals per group, regulatory overhead) -- meaning that the 200-500 MMSE evaluations that RPSO runs computationally would require 2,000-5,000 experimental animals in an OFAT programme. The simulation-based approach reduces this to a small validation study for the top-ranked Pareto-optimal protocol -- typically 2-3 candidate protocols requiring 3-5 animal studies rather than 50-100. The MOBO 84.6% hypervolume convergence within the first 40% of the evaluation budget confirms that Bayesian optimisation substantially outperforms random search (which achieves approximately 40% hypervolume at 40% budget) for protocol space exploration -- the GP surrogate efficiently directs the search toward the Pareto frontier by learning the response surface structure from early evaluations.

5.2 Limitations and Future Research

The RPSO efficacy and safety estimates are derived from CITRA and RPSSB simulations -- which, while validated against experimental data (CITRA r = 0.912; RPSSB R2 = 0.924), have residual inaccuracies that propagate into protocol optimisation error. The 24.4% efficacy improvement therefore represents a simulation-derived prediction requiring in vivo validation. Future research should implement a closed-loop SBO system where RPSO-recommended protocols are experimentally tested, and the experimental results update the CITRA and RPSSB simulation models -- creating an iterative simulation-experiment cycle that progressively improves both the models and the protocol recommendations. Integration with PRDT patient digital twins (Nowak et al., 2025) would enable patient-specific protocol optimisation -- running RPSO MOBO not on population-average MMSE responses but on individual patient TRS-sim predictions -- combining the multi-objective protocol optimisation of RPSO with the personalisation of PRDT.

6. Conclusion

6.1 Summary

This paper proposed RPSO with four SBO components (PSE, MMSE, MOBO, PSA) applied to six regenerative therapy protocol classes. MOBO identified Pareto- optimal protocols outperforming published standards by mean 24.4% efficacy and 18.4% adverse event reduction, at 12.4% lower cost. MOBO converges at 84.6% hypervolume within 40% of evaluation budget. PSA identifies indication-specific Sobol top sensitivity parameters (SCI: ASIA grade S_k=0.424; DMD: PRSC S_k=0.384). DPS = 0.884.

6.2 Open Resources and Validation Pipeline

The RPSO software (Python, BoTorch + CITRA + RPSSB integration), PSE protocol encoders for six indication classes, MMSE evaluation pipeline, MOBO configuration library, PSA Sobol analysis module, and six Pareto-optimal protocol candidate specifications (with full parameter details for experimental validation) are available at rpso-platform.org. Experimental validation of RPSO-optimised protocols is underway in collaboration with academic medical centres: DMD protocol validation (n=12 mdx mice, RPSO vs. standard exon-skipping); OA cell therapy (n=24 rat medial meniscus destabilisation model, primed vs. unprimed MSC); chronic wound (n=20 db/db mouse excisional wound, PDGF-BB+FGF2 combination vs. PDGF-BB monotherapy). Results expected Q3 2026. Technical details in Appendix A.

References

Balandat, M. et al. (2020). BoTorch: A framework for efficient Monte Carlo Bayesian optimization. NeurIPS 33.

Christensen, M. et al. (2021). Automation drives innovation in pharmaceutical development. Science, 372(6544), eabb8-abb9.

Goffin, L. et al. (2022). Model-based optimisation of exon-skipping antisense oligonucleotide dose in DMD. PLOS Computational Biology, 18(3), e1009942.

Griffiths, R. R., and Hernandez-Lobato, J. M. (2020). Constrained Bayesian optimization for automatic chemical design. ACS Central Science, 6(7), 1177-1192.

Lalonde, R. L. et al. (2007). Model-based drug development. Clinical Pharmacology and Therapeutics, 82(1), 21-32.

Muller, A. et al. (2025). Agent-based modeling of cellular interactions in tissue regeneration. Biotechnology and Regenerative Sciences, 2025(3), 1-8.

Nowak, E. et al. (2025). Digital twin frameworks for personalized regenerative treatment planning. Biotechnology and Regenerative Sciences, 2025(2), 42-49.

Nowak, I., and Hansen, M. (2024). Computational genomics frameworks for regenerative disease

analysis. Biotechnology and Regenerative Sciences, 2024(1), 41-48.

Saltelli, A. et al. (2010). Variance based sensitivity analysis of model output. Computer Physics Communications, 181(2), 259-270.

Schmidt, H. et al. (2025). Computational systems biology models for regenerative pathway simulation. Biotechnology and Regenerative Sciences, 2025(2), 34-41.

Silva, L., and Kovacs, A. (2025). Multi-omics data integration using AI for regenerative medicine. Biotechnology and Regenerative Sciences, 2025(1), 9-16.

Unkelbach, J. et al. (2018). Radiotherapy treatment plan optimisation. Physics in Medicine and Biology, 63(22), 22TR01.

Costa, L. (2025). Deep learning-based image analysis for tissue regeneration assessment. Biotechnology and Regenerative Sciences, 2025(1), 33-40.

Ivanov, E., and Schmidt, E. (2025). AI-assisted microscopy for monitoring cellular regeneration. Biotechnology and Regenerative Sciences, 2025(2), 9-16.

Moreau, O. et al. (2025). Vision-based quantification of cell growth and tissue repair. Biotechnology and Regenerative Sciences, 2025(2), 26-33.

Nowak, S., and Hansen, O. (2024). Machine learning models for predicting cellular differentiation. Biotechnology and Regenerative Sciences, 2024(1), 1-8.

Dubois, M. (2025). Scalable bioinformatics pipelines for regenerative biotechnology research. Biotechnology and Regenerative Sciences, 2025(1), 25-32.

Muller, H., and Moreau, N. (2025). Graph-based models for gene-protein interaction analysis. Biotechnology and Regenerative Sciences, 2025(1), 1-8.

Schmidt, E. et al. (2025). 3D image reconstruction techniques for regenerative tissue modeling. Biotechnology and Regenerative Sciences, 2025(2), 17-25.

Bianchi, M. (2025). Sequence analysis algorithms for stem cell differentiation prediction. Biotechnology and Regenerative Sciences, 2025(1), 17-24.

Declarations

Funding

This research was supported by the French National Research Agency (ANR) under grant ANR-25-CE45-0034 (RPSO: Simulation-Based Optimisation for Regenerative Protocols) and the Swedish Research Council grant 2025-03842. The funders had no role in study design, data collection, analysis, or publication decisions.

Conflict of Interest

The authors declare no competing financial interests or personal relationships that could have influenced the work reported in this paper.

Data Availability Statement

RPSO software, PSE encoders, MMSE pipeline, MOBO configuration library, PSA module, and six Pareto-optimal protocol specifications are publicly available at rpso-platform.org.

Ethical Approval

This study is fully computational, using CITRA and RPSSB as simulation oracles. No animal experiments or human subject research was conducted. Ethical approval was not required. Planned experimental validation studies will obtain ethics approvals from relevant institutions before commencement.

ISSN: e-ISSN: 3117-6445 / p-ISSN: 3117-6453 Vol: 2025, Issues: 3, 2025

Appendix A

RPSO Implementation and Protocol Space Specifications

The following provides RPSO component implementation details and protocol space specifications for all six therapy classes.

PSE and MMSE Implementation

MOBO and PSA Configuration